P/E ratio for Roche (ROG.SW)

P/E ratio history for Roche from 2001 to 2022

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Johnson & Johnson JNJ	10.4	-39.52%	🇺🇸 USA
Merck MRK	54.9	219.59%	🇺🇸 USA
Pfizer PFE	14.2	-17.32%	🇺🇸 USA
Sanofi SNY	15.4	-10.46%	🇫🇷 France
Novartis NVS	26.5	54.17%	🇨🇭 Switzerland
GlaxoSmithKline GSK	9.78	-43.11%	🇬🇧 UK
Abbott Laboratories ABT	38.1	121.78%	🇺🇸 USA
Amgen AMGN	18.8	9.36%	🇺🇸 USA
Becton Dickinson BDX	40.7	136.55%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.